Bristol-Myers Squibb's Opdivo is in more vaccine combo studies than its PD-1/PD-L1 rivals, according to a new report.
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…
European biotech Vaximm has partnered with much bigger drug companies Merck KGaA and Pfizer to test a cancer vaccine/checkpoint inhibitor combo.
Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.
Bavarian Nordic has licensed a cell line from Valneva to help it manufacture vaccines based on its modified vaccinia Ankara vaccine platform.
GlaxoSmithKline’s U.S. vaccine R&D head Ripley Ballou says emerging disease vaccine research needs a shakeup—and here's how.
The U.S. government is pumping more money into anthrax bioterror preparedness.
Protein Sciences will start the search for two new H7N9 vaccine candidates by request of the HHS’ Biomedical Advanced Research and Development Authority.
Astellas just forged a licensing deal with Affinivax to develop a pneumococcal vaccine. Their target? Pfizer’s Prevnar 13—the world’s best-selling vaccine.
Brazil’s health authority will expand its yellow fever vaccine stockpile by 11.5 million doses as an outbreak rages in the country. Previous outbreaks in…